An official ATS statement: Hepatotoxicity of antituberculosis therapy

American Journal of Respiratory and Critical Care Medicine

Volumn 174, Issue 8, 2006, Pages 935-952

  Saukkonen, Jussi J ^a   Cohn, David L ^a   Jasmer, Robert M ^a   Schenker, Steven ^a   Jereb, John A ^a   Nolan, Charles M ^a   Peloquin, Charles A ^a   Gordin, Fred M ^a   Nunes, David ^a   Strader, Dorothy B ^a   Bernardo, John ^a   Venkataramanan, Raman ^a   Sterling, Timothy R ^a  

^a NONE

Author keywords

Hepatitis; Latent tuberculosis; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALLOPURINOL; ANTIRETROVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITOXIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KETOCONAZOLE; LEVOFLOXACIN; LIVER ENZYME; METHOTREXATE; MINOCYCLINE; OFLOXACIN; PARACETAMOL; PHENYTOIN; PREDNISONE; PYRAZINAMIDE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SIMVASTATIN; STEROID; SULFONAMIDE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALCOHOLIC FATTY LIVER; ARTICLE; BRUCELLOSIS; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DRUG BILE LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG LIVER LEVEL; DRUG METABOLISM; ENZYME BLOOD LEVEL; FATALITY; GRANULOMATOUS HEPATITIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LIVER FAILURE; LIVER FUNCTION; LIVER INJURY; LIVER STRUCTURE; LIVER TOXICITY; MEDICAL RESEARCH; META ANALYSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TOXIC HEPATITIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; CONGRESSES; HUMANS; LIVER; LIVER DISEASES; RISK FACTORS; SOCIETIES, MEDICAL; TUBERCULOSIS;

EID: 33749856322     PISSN: 1073449X     EISSN: 1073449X     Source Type: Journal    
DOI: 10.1164/rccm.200510-1666ST     Document Type: Article

References (184)

1. Lee J, Boyer JL. Molecular alterations in hepatocyte transport. Semin Liver Dis 2000;20:373-384.
2. Hilsden RJ, Shaffer E. Liver structure and function. In: Thomson A, Shaffer E, editors. First principles of gastroenterology: the basis of disease and an approach to management, 4th ed. Edmonton, AB, Canada: Astra; 2000. pp. 462-564.
3. Benichou C. Criteria for drug-induced liver disorder: report of an international consensus meeting. J Hepatol 1990;11:272-276.
4. Chitturi S, Farrell G. Drug-induced liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Schiff's diseases of the liver, 9th ed. Philadelphia: Lippincott, Williams & Wilkins; 2002. pp. 1059-1128.
5. Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145-155.
6. Ostapowicz GM, Fontana R, Schiødt F, Larson A, Davern T, Steven Han H, McCashland T, Shakil A, Hay J, Hynan L, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
7. American Society of Health-Systems Pharmacists. American Hospital Formulary Service (AHFS) drug information [CD-ROM]. Gerald K. McEvoy, ed. Marlborough, MA: Skyscape; 2005.
8. Carson JL, Strom BL, Duff A, Gupta A, Das K. Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med 1993;153:1331-1336.
9. Brown SJ, Desmond PV. Hepatotoxicity of antimicrobial agents. Semin Liver Dis 2002;22:157-167.
10. Kaplowitz N. Drug-induced liver injury. Clin Infect Dis 2004;38:S44-S48.
11. U.S. Public Health Service. Hepatic toxicity of pyrazinamide used with isoniazid in tuberculous patients. Am Rev Respir Dis 1969;59:13.
12. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002;22:137-144.
13. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury: I. Performance characteristics of laboratory tests. Clin Chem 2000;46:2027-2049.
14. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury: II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-2068.
15. American Gastroenterologic Association Clinical Practice Committee. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002;123:1367-1384.
16. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
17. Rosenzweig P, Miget N, Brohier S. Transaminase elevation on placebo during phase I trials: prevalence and significance. Br J Clin Pharmacol 1999;48:19-23.
18. Williams GM, Iatropoulos MJ. Alteration of liver cell function and proliferation: differentiation between adaptation and toxicity. Toxicol Pathol 2002;30:41-53.
19. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity. Chest 2003;123:102-106.
20. Turktas H, Unsal M, Tulek N, Oruc O. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazid and pyrazinamide) or viral hepatitis. Tuber Lung Dis 1994;75:58-60.
21. Kumar A, Misra PK, Mehotra R, Govil YC, Rana GS. Hepatotoxicity of rifampin and isoniazid: is it all drug-induced hepatitis? Am Rev Respir Dis 1991;143:1350-1352.
22. Dielh AM. Cytokine regulation of liver injury and repair. Immunol Rev 2000;174:160-171.
23. Amacher D. Serum transaminase elevations as indicators of hepatic injury following the administration of drugs. Regul Toxicol Pharmacol 1998;27:119-130.
24. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: a prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989;32:121-127.
25. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002;2:11-19.
26. Martin-Carbonero L, Nunez M, Gonzalez-Lahoz J, Soriano V. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003;4:115-120.
27. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003;33:146-152.
28. Langman G, Hall PM, Todd G. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001;16:1395-1401.
29. Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapy. Int J STD AIDS 2001;12:555-562.
30. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002;22:185-194.
31. Gronhagen-Riska C, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978;118:461-466.
32. Tanaka E, Terada M, Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 2000;25:165-175.
33. Lieber CS. Susceptibility to alcohol-related liver injury. Alcohol Alcohol Suppl 1994;2:315-326.
34. Kanathur N, Mathai MG, Byrd RP, Fields CL, Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001;94:339-341.
35. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002;6:699-705.
36. Fernandez-Villar A, Sopena B, Vazquez R, Ulloa F, Fluiters E, Mosteiro M, Martinez-Vazquez C, Pineiro L. Isoniazid hepatotoxicity among drug users: the role of hepatitis C. Clin Infect Dis 2003;36:293-298.
37. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS, Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003;34:S21-S33.
38. Massacesi C, Santini D, Rocchi MB, La Cesa A, Marcucci F, Vincenzi B, Delprete S, Tonini G, Bonsignori M. Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Anticancer Drugs 2003;14:533-541.
39. Suzuki Y, Uehara R, Tajima C, Noguchi A, Ide M, Ichikawa Y, Mizushima Y. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate: risk factors and response to folic acid. Scand J Rheumatol 1999;28:273-281.
40. Schenker S, Martin RR, Hoyumpa AM. Antecedent liver disease and drug toxicity. J Hepatol 1999;31:1098-1105.
41. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-S247.
42. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005;26:462-464.
43. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002;167:131-136.
44. Ridzon R, Meador J, Maxwell R, Higgins K, Weismuller P, Onorato IM. Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin. Clin Infect Dis 1997;24:1264-1265.
45. Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, Chang FY, Lee SD. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-889.
46. Huang YS, Chern HD, Su WJ, Wu JC, Chang SC, Chiang CH, Chang FY, Lee SD. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003;37:924-930.
47. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 1997;34:758-760.
48. Mitchell JR, Thorgeirsson UP, Black M, Timbrell JA, Snodgrass WR, Potter WZ, Jollow HR, Keiser HR. Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydrazine metabolites. Clin Pharmacol Ther 1975;18:70-79.
49. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986;6:295-298.
50. Dickinson DS, Bailey WC, Hirschowitz BI, Soong SJ, Eidus L, Hodgkin MM. Risk factors for isoniazid (INH)-induced liver dysfunction. J Clin Gastroenterol 1981;3:271-279.
51. Gurumurthy P, Krishnamurthy MS, Nazareth O, Parthasarathy R, Sarma GR. Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis. Am Rev Respir Dis 1984;129:58-61.
52. Attri S, Rana SV, Vaiphie K, Katyal R, Sodhi CP, Kanwar S, Singh K. Protective effect of N-acetylcysteine in isoniazid induced hepatic injury in growing rats. Indian J Exp Biol 2001;39:436-440.
53. Sodhi CP, Rana SV, Mehta SK, Vaiphei K, Attri S, Thakur S, Mehta S. Study of oxidative stress in isoniazid-induced hepatic injury in young rats with and without protein-energy malnutrition. J Biochem Toxicol 1996;11:139-146.
54. Mitchell JR, Zimmerman HJ, Ishak KG, Thorgeirsson UP, Timbrell JA, Snodgrass WR, Nelson SD. Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 1976;84:181-192.
55. Desta Z, Soukhova NV, Flockhart DA. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 2001;45:382-392.
56. Tanaka E, Terada M, Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. J Clin Pharm Ther 2000;25:165-175.
57. O'Shea D, Kim RB, Wilkinson GR. Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Pharmacol 1997;43:99-103.
58. Dickinson D, Bailey W, Hirschowitz B. The effect of acetylation status on isoniazid (INH) hepatitis. Am Rev Respir Dis 1977;115:395.
59. Sarma GR, Immanuel C, Kailasam S, Narayana AS, Venkatesan P. Rifampin-induced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986;133:1072-1075.
60. Scharer L, Smith JP. Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid. Ann Intern Med 1969;71:1113-1120.
61. Ferebee S, Mount F. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis 1962;85:490-510.
62. Garibaldi R, Drusin R, Ferebee S, Gregg M. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 1972;106:357-365.
63. Kopanoff DE, Snider D, Caras G. Isoniazid related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis 1979;117:991-1001.
64. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ 1982;60:555-564.
65. Centers for Disease Control and Prevention, American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-739.
66. Nolan CM, Goldberg S, Buskin S. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018.
67. LoBue PA, Moser KS. Isoniazid- and rifampin-resistant tuberculosis in San Diego County, California, United States, 1993-2002. Int J Tuberc Lung Dis 2005;9:501-506.
68. Fountain FF, Tolley E, Chrisman CR, Self TH. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116-123.
69. Millard PS, Wilcosky T, Reade-Christopher S, Weher D. Isoniazid-related fatal hepatitis. West J Med 1996;164:486491.
70. Snider DE, Caras G. Isoniazid-associated hepatitis deaths: a review of available information. Am Rev Respir Dis 1992;145:494-497.
71. Franks A, Binkin N, Snider D, Rokaw W, Becker S. Isoniazid hepatitis among pregnant and postpartum Hispanic patients. Public Health Rep 1989;104:151-155.
72. Comstock G. Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks. JAMA 1986;256:2729-2730.
73. Crippin JS. Acetaminophen hepatotoxicity: potentiation by isoniazid. Am J Gastroenterol 1993;88:590-592.
74. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003;62:1241-1242.
75. Berkowitz FE, Henderson SL, Fajman N, Schoen B, Naughton M. Acute liver failure caused by isoniazid in a child receiving carbamazepine. Int J Tuberc Lung Dis 1998;2:603-606.
76. Bucher HC, Griffith L, Guyatt G, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999;13:501-507.
77. McGlynn KA, Lustbader ED, Sharrar RG, Murphy EC, London WT. Isoniazid prophylaxis in hepatitis B carriers. Am Rev Respir Dis 1986;134:666-668.
78. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol 2002;97:1198-1203.
79. Sadaphal P, Astemborski J, Graham NM, Sheely L, Bonds M, Madison A, Vlahov D, Thomas D, Sterling T. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis 2001;33:1687-1691.
80. Grosset J, Leventis S. Adverse effects of rifampin. Rev Infect Dis 1983;5:S440-S450.
81. Capelle P, Dhumeaux D, Mora M, Feldmann G, Berthelot P. Effect of rifampicin on liver function in man. Gut 1972;13:366-371.
82. Gabriel R. Rifampicin jaundice. BMJ 1971;3:182.
83. Erdil A, Kadayifci A, Ates Y, Bagci S, Uygun A, Dagalp K. Rifampicin test in the diagnosis of Gilbert's syndrome. Int J Clin Pract 2001;55:81-83.
84. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004;170:445-449.
85. Hong Kong Chest Service, Tuberculosis Research Centre, Madras, British Medical Research Council. A double-blind placebo-controlled clinical trial of three anti-tuberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.
86. Cascio A, Scarlata F, Giordano S, Antinori S, Colomba C, Titone L. Treatment of human brucellosis with rifampin plus minocycline. J Chemother 2003;15:248-252.
87. Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992;102:2077-2080.
88. Prince MI, Burt AD, Jones DE. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002;50:436-439.
89. Byrne JA, Strautnieks SS, Mieli-Vergani G, Higgins CF, Linton KJ, Thompson RJ. The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 2002;123:1649-1658.
90. Covic A, Goldsmith D, Segall L, Stoicescu C, Lungu S, Volovat C, Covic M. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant 1998;13:924-929.
91. Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Medicine 1999;78:361-369.
92. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996;93:4001-4005.
93. Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, Wojnowski L. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 2004;279:38379-38385.
94. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001;299:849-857.
95. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-850.
96. Scheuer PJ, Summerfield JA, Lal S, Sherlock S. Rifampicin hepatitis: a clinical and histological study. Lancet 1974;1:421-425.
97. Polesky A, Farber H, Gottlieb D, Park H, Levinson S, O'Connell J, McInnis B, Nieves R, Bernardo J. Rifampin preventive therapy for tuberculosis in Boston's homeless. Am J Respir Crit Care Med 1996;154:1473-1477.
98. Villarino ME, Ridzon R, Weismuller PC, Elcock M, Maxwell RM, Meador J, Smith PJ, Carson ML, Geiter LJ. Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997;155:1735-1738.
99. McNab BD, Marciniuk DD, Alvi RA, Tan L, Hoeppner VH. Twice-weekly isoniazid and rifampin treatment of latent tuberculosis infection in Canadian plains Aborigines. Am J Respir Crit Care Med 2000;162:989-993.
100. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin: a meta-analysis. Chest 1991;99:465-471.
101. Lacroix C, Tranvouez JL, Phan Hoang T, Duwoos H, Lafont D. Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency. Arzneimittelforschung 1990;40:76-79.
102. Moriwaki Y, Yamamoto T, Nasako Y, Takahashi S, Suda M, Hiroishi K, Hada T, Higashino K. In vitro oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase. Biochem Pharmacol 1993;46:975-981.
103. Yamamoto T, Moriwaki Y, Suda M, Nasako Y, Takahashi S, Hiroishi K, Nakano T, Hada T, Higashino K. Effect of BOF-4272 on the oxidation of allopurinol and pyrazinamide in vivo: is xanthine dehydrogenase or aldehyde oxidase more important in oxidizing both allopurinol and pyrazinamide? Biochem Pharmacol 1993;46:2277-2284.
104. Nasu S, Yamaguchi K, Sakakibara S, Imai H, Ueda I. The effect of pyrazines on the metabolism of tryptophan and nicotinamide adenine dinucleotide in the rat: evidence of the formation of a potent inhibitor of aminocarboxy-muconate-semialdehyde decarboxylase from pyrazinamide. Biochim Biophys Acta 1981;677:109-119.
105. Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K. Study of the metabolism of pyrazinamide using a high-performance liquid chromatographic analysis of urine samples. Anal Biochem 1987;160:346-349.
106. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Morbid Mortal Wkly Rep 2003;52:1-88.
107. Shibata K, Fukuwatari T, Sugimoto E. Effects of dietary pyrazinamide, an antituberculosis agent, on the metabolism of tryptophan to niacin and of tryptophan to serotonin in rats. Biosci Biotechnol Biochem 2001;65:1339-1346.
108. Centers for Disease Control and Prevention, American Thoracic Society. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:733-735.
109. Knobel B, Buyanowsky G, Dan M, Zaidel L. Pyrazinamide-induced granulomatous hepatitis. J Clin Gastroenterol 1997;24:264-266.
110. Urban T, Maquarre E, Housset C, Chouaid C, Devin E, Lebeau B. Allopurinol hypersensitivity: a possible cause of hepatitis and mucocutaneous eruptions in a patient undergoing antitubercular treatment. Rev Mal Respir 1995;12:314-316.
111. Lacroix C, Guyonnaud C, Chaou M, Duwoos H, Lafont O. Interaction between allopurinol and pyrazinamide. Eur Respir J 1988;1:807-811.
112. Centers for Disease Control and Prevention, American Thoracic Society. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2002;51:998-999.
113. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000;283:1445-1450.
114. Gordin FM, Cohn DL, Matts JP, Chaisson RE, O'Brien RJ. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis 2004;39:561-565.
115. Halsey NA, Coberly J, Desormeaux J, Losikoff P, Atkinson J, Moulton L, Contave M, Johnson M, Davis H, Geiter L, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Lancet 1998;35I:786-792.
116. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457.
117. Geiter L, O'Brien R, Kopanoff D. Short-course preventive therapy for tuberculosis [abstract]. Am Rev Respir Dis 1990;141:A437.
118. Geiter L. Results of a randomized, controlled trial to assess the toxicity and patient adherence with two short-course regimens for the prevention of tuberculosis, a two-month regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six months-isoniazid [thesis]. Baltimore, MD: Johns Hopkins University, School of Hygiene and Public Health; 1997.
119. Grazcyk J, O'Brien R, Bek E, Nimerowsak H, Geiter L. Assessment of rifampin containing regimens for tuberculosis preventive therapy: preliminary results from a pilot study in Poland [abstract]. Am Rev Respir Dis 1991;143:A119.
120. Magdorf K, Arizzi-Ruche A, Geiter L, O'Brien R, Wahn U. Compliance and tolerance of new antituberculotic short term chemoprevention regimes in childhood: a pilot study. Pneumologie 1994;48:761-764.
121. Bock NN, Rogers T, Tapia JR, Herron GD, DeVoe B, Geiter LJ. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest 2001;119:833-837.
122. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: amulticenter clinical trial. Ann Intern Med 2002;137:640-647.
123. Lobato MN, Leary L. Adverse drug effects and treatment outcomes related to treatment for latent tuberculosis infection using rifampin and pyrazinamide. Chest 2005;127:1296-1303.
124. Chaisson RE, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners [letter]. JAMA 2002;288:165-166.
125. van Hest R, Baars H, Kik S, van Gerven P, Trompenaars MC, Kalisvaart N, Keizer S, Borgdorff M, Mensen M, Cobelens F. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis 2004;39:488-496.
126. Stout JE, Engemann JJ, Cheng AC, Fortenberry ER, Hamilton CD. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003;167:824-827.
127. Perucca E, Grimaldi R, Frigo GM, Sardi A, Monig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34:595-599.
128. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-598.
129. Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000;181:1289-1297.
130. Havlir DV, Dube MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC Jr, Witt MD, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996;335:392-398.
131. Gulliford M, Mackay AD, Prowse K. Cholestatic jaundice caused by ethambutol. Br Med J (Clin Res Ed) 1986;292:866.
132. Bertino J Jr, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000;22:798-817.
133. Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med 1991;91:153S-161S.
134. Dombeck M, Duch D, Bennet S, Bell L. Evaluating the implications of long-term safety and efficacy on the use of fluoroquinolones in the treatment of pulmonary tuberculosis. Research Triangle Park, NC: RTI Health Solutions; 2001.
135. Ball P. Long-term use of quinolones and their safety. Rev Infect Dis 1989;11:S1365-S1370.
136. Lazarczyk DA, Goldstein NS, Gordon SC. Trovafloxacin hepatotoxicity. Dig Dis Sci 2001;46:925-926.
137. Labowitz JK, Silverman WB. Cholestatic jaundice induced by ciprofloxacin. Dig Dis Sci 1997;42:192-194.
138. Coleman CI, Spencer JV, Chung JO, Reddy P. Possible gatifloxacin-induced fulminant hepatic failure. Ann Pharmacother 2002;36:1162-1167.
139. Kahn JB. Latest industry information on the safety profile of levofloxacin in the US. Chemotherapy 2001;47:32-37.
140. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004;26:940-950.
141. Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol 2001;16:1028-1032.
142. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996;77:37-42.
143. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003;167:1472-1477.
144. Dossing M, Wilcke JT, Askgaard DS, Nybo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996;77:335-340.
145. Teleman MD, Chee CB, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002;6:699-705.
146. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-2030.
147. Hwang SJ, Wu JC, Lee CN, Yen FS, Lu CL, Lin TP, Lee SD. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997;12:87-91.
148. Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, Echizen H, Ogata H. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002;72:220-226.
149. Tsagaropoulou-Stinga H, Mataki-Emmanouilidou T, Karida-Kavalioti S, Manios S. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr Infect Dis 1985;4:270-273.
150. Parthasarathy R, Sarma GR, Janardhanam B, Ramachandran P, Santha T, Sivasubramanian S, Somasundaram PR, Tripathy SP. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle 1986;67:99-108.
151. O'Brien RJ, Long MW, Cross FS, Lyle MA, Snider DE Jr. Hepatotoxicity from isoniazid and rifampin among children treated for tuberculosis. Pediatrics 1983;72:491-499.
152. Algerian Working Group/British Medical Research Council cooperative study. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis 1984;129:921-928.
153. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004;38:1074-1079.
154. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990;112:407-415.
155. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1985;132:374-378.
156. Neill P, Pringle D, Mhonda M, Kusema T, Nhachi CF. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population. Cent Afr J Med 1990;36:104-107.
157. Hwang SJ, Wu JC, Lee CN, Yen F, Lu C, Lin T, Lee S. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997;12:87-91.
158. Martinez-Roig A, Cami J, Llorens-Terol J, de la Torre R, Perich F. Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children. Pediatrics 1986;77:912-915.
159. Singh J, Garg PK, Tandon RK. Hepatotoxicity due to antituberculosis therapy: clinical profile and reintroduction of therapy. J Clin Gastroenterol 1996;22:211-214.
160. Krishnaswamy K, Prasad CE, Murthy KJ. Hepatic dysfunction in undernourished patients receiving isoniazid and rifampicin. Trop Geogr Med 1991;43:156-160.
161. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-919.
162. Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, Majumder PP. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001;16:1033-1037.
163. Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 2000;69:64-69.
164. Howell F, O'Laoide R, Kelly P, Power J, Clancy L. Short course chemotherapy for pulmonary tuberculosis: a randomised controlled trial of a six month versus a nine month oral regimen. Ir Med J 1989;82:11-13.
165. Zierski M, Bek E. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis: a controlled clinical study. Tubercle 1980;61:41-49.
166. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity and acceptability: report of the final results. Ann Intern Med 1990;112:397-406.
167. Cohen CD, Sayed AR, Kirsch RE. Hepatic complications of antituberculosis therapy revisited. S Afr Med J 1983;63:960-963.
168. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med 1991;324:289-294.
169. European Tuberculosis Study Group. Tuberculosis in HIV-infected patients: amulticentric randomized comparative study of a three- versus a four-drug regimen [abstract PoB3077]. Presented at the Eighth International Conference on AIDS/III STD World Congress; 1992;Amsterdam, Netherlands.
170. El-Sadr WM, Perlman DC, Matts JP, Nelson E, Cohn D, Salomon N, Olibrice M, Medard F, Chirgwin K, Mildvan D, et al. Evaluation of an intensive intermittent-induction regimen and duration of shortcourse treatment for human immunodeficiency virus-related pulmonary tuberculosis. Clin Infect Dis 1998;26:1148-1158.
171. Dworkin MS, Adams MR, Cohn DL, Davidson A, Buskin S, Horwitch C, Morse A, Sackoff J, Thompson M, Wotring L, et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr 2005;39:464-470.
172. Chaisson RE, Clermont HC, Holt EA, Cantave M, Johnson M, Atkinson J, Davis H, Boulos R, Quinn T, Halsey N. Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection. Am J Respir Crit Care Med 1996;154:1034-1038.
173. Ungo JR, Jones D, Ashkin D, Hollender E, Bernstein D, Albanese A, Pitchenik A. Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-1876.
174. Wu JC, Lee SD, Yeh PF, Chan C, Wang Y, Huang Y, Tsai Y, Lee P, Ting L, Lo K. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502-504.
175. Wong WM, Wu PC, Yuen MF, Cheng C, Yew W, Wong P, Tam C, Leung C, Lai C. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-206.
176. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, Kwon OJ. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-1311.
177. Pernod J. Hepatic tolerance of ethionamide. Am Rev Respir Dis 1965;92:39-42.
178. Phillips S, Tashman H. Ethionamide jaundice. Am Rev Respir Dis 1963;87:896-898.
179. British Tuberculosis Association. A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association. Tubercle 1968;49:125-135.
180. Somner AR, Brace AA. Changes in serum transaminase due to prothionamide. Tubercle 1967;48:137-143.
181. Rossouw JE, Saunders SJ. Hepatic complications of antituberculous therapy. Q J Med 1975;XLIV:1-16.
182. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B: update of recommendations. Hepatology 2004;39:857-861.
183. World Health Organization. Treatment of tuberculosis: guidelines for national programmes, 2nd ed. Geneva, Switzerland: World Health Organization; 1997. Publication No. WHO/TB/97.220.
184. Enarson D, Rieder H, Arnadottir T, Trébucq A. Management of tuberculosis: a guide for low income countries, 5th ed. Paris: International Union Against Tuberculosis and Lung Disease; 2000. Available from: http://www.iuatld.org/pdf/en/guides_publications/management_of_tb.pdf